Current and Future Therapies Targeting the Immune System in Multiple Sclerosis

ISSN: 1873-4316 (Online)
ISSN: 1389-2010 (Print)

Volume 16, 12 Issues, 2015

Download PDF Flyer

Current Pharmaceutical Biotechnology

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 152nd of 255 in Pharmacology & Pharmacy
  • 213th of 290 in Biochemistry & Molecular Biology

Submit Abstracts Online Submit Manuscripts Online

Zeno Foldes-Papp
Visiting Professor of Medical Biochemistry
HELIOS Clinical Center of Emergency Medicine
Department for Internal Medicine
Alte-Koelner-Strasse 9
D-51688 Koeln-Wipperfuerth

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 1.95
5 - Year: 2.558

Current and Future Therapies Targeting the Immune System in Multiple Sclerosis

Current Pharmaceutical Biotechnology, 15(3): 276-296.

Author(s): Verena Loleit, Viola Biberacher and Bernhard Hemmer.

Affiliation: Department of Neurology, Klinikum rechts der Isar, Technische Universität München, Ismaninger Strasse 22, 81675 Munich, Germany.


Multiple sclerosis (MS) is a demyelinating disease of the central nervous system (CNS). The exact pathomechanism is unknown, but an aberrant immune response against CNS antigens, leading to inflammation in brain and spinal cord followed by demyelination, axonal damage and scar formation, seems to play a major role. Later in the disease course, inflammation decreases, while neurodegeneration proceeds. Approximately 80% of the patients initially show a relapsing-remitting disease course (RRMS), but the majority of them later develops a secondary progressive MS (SPMS). A minority suffers from primary progressive MS (PPMS). Primary goals of long-term MS therapy are to prevent relapses and disease progression. Assuming that MS is an autoimmune disease, most therapeutics aim to modulate or suppress the immune system. Until now many drugs have proven efficacy in RRMS, but none in PPMS. Interferon-β (IFN-β) and glatiramer acetate are known in RRMS therapy for years. Based on preclinical research and clinical trials, new treatment strategies have emerged and have been transferred from bench to bedside. The α4β-integrin-antagonist natalizumab was approved in 2005. Fingolimod, dimethyl fumarate and teriflunomide were the first oral drugs introduced in MS therapy. Recently alemtuzuab, another monoclonal antibody, was approved in Europe. Promising future perspectives are alemtuzumab, daclizumab, and laquinimod. Here, we review drug mechanisms in the therapy of MS. The mechanisms of action and the effect of the drugs on the immune system are summarized. We report recent results of clinical trials, highlight special features of different treatment strategies, and discuss future perspectives and ongoing clinical trials.


Dimethyl fumarate, fingolimod, glatiramer acetate, interferons, multiple sclerosis, natalizumab, teriflunomide.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 15
Issue Number: 3
First Page: 276
Last Page: 296
Page Count: 21
DOI: 10.2174/1389201015666140617104332

Related Journals

Webmaster Contact: Copyright © 2015 Bentham Science